Jitka Malčíková, Ph.D.

Publications that are part of the Web of Science database, possibly also other publications chosen by authors.

2020

• Jaskova, Z; Pavlova, S; Malcikova, J; Brychtova, Y; Trbusek, M, 2020: PRIMA-1(MET) cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells. LEUKEMIA RESEARCH 89, doi: 10.1016/j.leukres.2019.106288
• Malcikova, J; Pavlova, S; Vonkova, B; Kotaskova, J; Radova, L; Plevova, K; Zenatova, M; Hynst, J; Dvorackova, B; Panovska, A; Brychtova, Y; Tichy, B; Navrkalova, V; Pal, K; Mayer, J; Doubek, M; Pospisilova, S, 2020: Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact. LEUKEMIA & LYMPHOMA 61, p. 222 - 224

2018

• Brazdilova, K; Plevova, K; Francova, HS; Kockova, H; Borsky, M; Bikos, V; Malcikova, J; Oltova, A; Kotaskova, J; Tichy, B; Brychtova, Y; Mayer, J; Doubek, M; Pospisilova, S, 2018: Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL. LEUKEMIA 32(1), p. 234 - 236, doi: 10.1038/leu.2017.274
• Kubesova, B; Pavlova, S; Malcikova, J; Kabathova, J; Radova, L; Tom, N; Tichy, B; Plevova, K; Kantorova, B; Fiedorova, K; Slavikova, M; Bystry, V; Kissova, J; Gisslinger, B; Gisslinger, H; Penka, M; Mayer, J; Kralovics, R; Pospisilova, S; Doubek, M, 2018: Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. LEUKEMIA 32(2), p. 450 - 461, doi: 10.1038/leu.2017.230
• Zaprazna, K; Basu, A; Tom, N; Jha, V; Hodawadekar, S; Radova, L; Malcikova, J; Tichy, B; Pospisilova, S; Atchison, ML, 2018: Transcription factor YY1 can control AID-mediated mutagenesis in mice. EUROPEAN JOURNAL OF IMMUNOLOGY 48(2), p. 273 - 282, doi: 10.1002/eji.201747065
• Malcikova, J; Tausch, E; Rossi, D; Sutton, LA; Soussi, T; Zenz, T; Kater, AP; Niemann, CU; Gonzalez, D; Davi, F; Diaz, MG; Moreno, C; Gaidano, G; Stamatopoulos, K; Rosenquist, R; Stilgenbauer, S; Ghia, P; Pospisilova, S, 2018: ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. LEUKEMIA 32(5), p. 1070 - 1080, doi: 10.1038/s41375-017-0007-7
• Tikkanen, T; Leroy, B; Fournier, JL; Risques, RA; Malcikova, J; Soussi, T, 2018: Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing. HUMAN MUTATION 39(7), p. 925 - 933, doi: 10.1002/humu.23543
• Tom, N; Tom, O; Malcikova, J; Pavlova, S; Kubesova, B; Rausch, T; Kolarik, M; Benes, V; Bystry, V; Pospisilova, S, 2018: ToTem: a tool for variant calling pipeline optimization. BMC BIOINFORMATICS 19, doi: 10.1186/s12859-018-2227-x

2017

• Plevova, K; Malcikova, J; Pavlova, S; Kotaskova, J; Poppova, L; Smardova, J; Diviskova, E; Durechova, K; Oltova, A; Brychtova, Y; Panovska, A; Doubek, M; Pospisilova, S, 2017: BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY. HAEMATOLOGICA 102, p. 65 - 66
• Kotaskova, J; Pavlova, S; Plevova, K; Malcikova, J; Stehlikova, O; Poppova, L; Kockova, H; Doubek, M; Bryja, V; Pospisilova, S, 2017: TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS. HAEMATOLOGICA 102, p. 414 - 414
• Malcikova, J; Kotaskova, J; Tom, N; Pal, K; Panovska, A; Brychtova, Y; Doubek, M; Pavlova, S; Pospisilova, S, 2017: Tracking low-burden TP53-mutated subclones during CLL treatment and remission using ROR1 separation. LEUKEMIA & LYMPHOMA 58, p. 162 - 163

2016

• Zaprazna, K; Malcikova, J; Tom, N; Radova, L; Trbusek, M; Atchison, M; Pospisilova, S, 2016: ACTIVATION INDUCED DEAMINASE SPLICE VARIANTS EXPRESSED IN B CELL LEUKEMIA AND LYMPHOMA DO NOT RETAIN THEIR CATALYTIC ACTIVITY. HAEMATOLOGICA 101, p. 429 - 430
• Kubesova, B; Pavlova, S; Malcikova, J; Kabathova, J; Radova, L; Tom, N; Tichy, B; Plevova, K; Kantorova, B; Fiedorova, K; Kissova, J; Gisslinger, B; Gisslinger, H; Mayer, J; Kralovics, R; Pospisilova, S; Doubek, M, 2016: Low-Burden TP53 Mutations Occur in Chronic Phase of Myeloproliferative Neoplasms Regardless of Hydroxyurea Administration, Disease Type, and JAK2 Status. BLOOD 128(22)
• Smardova, J; Liskova, K; Ravcukova, B; Malcikova, J; Hausnerova, J; Svitakova, M; Hrabalkova, R; Zlamalikova, L; Stano-Kozubik, K; Blahakova, I; Speldova, J; Jarkovsky, J; Smarda, J, 2016: Complex analysis of the p53 tumor suppressor in lung carcinoma. ONCOLOGY REPORTS 35(3), p. 1859 - 1867, doi: 10.3892/or.2015.4533
• Mareckov, A; Malcikova, J; Tom, N; Pal, K; Salek, D; Pospisilova, S; Trbusek, M, 2016: ATM GENE MUTATIONS REPRESENT A HALLMARK OF MANTLE CELL LYMPHOMA BUT DO NOT IMPACT PATIENTS´ SURVIVAL. HAEMATOLOGICA 101, p. 271 - 271
• Sutton, LA; Young, E; Baliakas, P; Hadzidimitriou, A; Moysiadis, T; Plevova, K; Rossi, D; Kminkova, J; Stalika, E; Pedersen, LB; Malcikova, J; Agathangelidis, A; Davis, Z; Mansouri, L; Scarfo, L; Boudjoghra, M; Navarro, A; Muggen, AF; Yan, XJ; Nguyen-Khac, F; Larrayoz, M; Panagiotidis, P; Chiorazzi, N; Niemann, CU; Belessi, C; Campo, E; Strefford, JC; Langerak, AW; Oscier, D; Gaidano, G; Pospisilova, S; Davi, F; Ghia, P; Stamatopoulos, K; Rosenquist, R, 2016: Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. HAEMATOLOGICA 101(8), p. 959 - 967, doi: 10.3324/haematol.2016.141812
• Pospisilova, S; Sutton, LA; Malcikova, J; Tausch, E; Rossi, D; Montserrat, E; Moreno, C; Stamatopoulos, K; Gaidano, G; Rosenquist, R; Ghia, P, 2016: Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?. HAEMATOLOGICA 101(3), p. 263 - 265, doi: 10.3324/haematol.2015.139246
• Jaskova, Z; Malcikova, J; Smardova, J; Brychtova, Y; Doubek, M; Trbusek, M, 2016: PRO-APOPTOTIC EFFECTS OF PRIMA-1MET CORRELATE WITH NOXA GENE INDUCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS. HAEMATOLOGICA 101, p. 226 - 226

2015

• Zemanova, J; Paruch, K; Krejci, L; Soucek, K; Hylse, O; Boudny, M; Borsky, M; Osickova, J; Khirsariya, P; Sebejova, L; Navrkalova, V; Malcikova, J; Diviskova, E; Brychtova, Y; Mayer, J; Trbusek, M, 2015: CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE HIGHLY SUSCEPTIBLE TO DIRECT INHIBITION OF CHECKPOINT KINASE 1. HAEMATOLOGICA 100, p. 417 - 417
• Jaskova, Z; Malcikova, J; Smardova, J; Brychtova, Y; Mayer, J; Trbusek, M, 2015: ELIMINATION OF MUTATED P53 PROTEIN AND INDUCTION OF P53 DOWNSTREAM GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS USING PRIMA-1MET. HAEMATOLOGICA 100, p. 414 - 414
• Kantorova, B; Malcikova, J; Smardova, J; Pavlova, S; Trbusek, M; Tom, N; Plevova, K; Tichy, B; Truong, S; Diviskova, E; Kotaskova, J; Oltova, A; Patten, N; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2015: TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. TUMOR BIOLOGY 36(5), p. 3371 - 3380, doi: 10.1007/s13277-014-2971-0
• Sutton, LA; Ljungstrom, V; Mansouri, L; Young, E; Cortese, D; Navrkalova, V; Malcikova, J; Muggen, AF; Trbusek, M; Panagiotidis, P; Davi, F; Belessi, C; Langerak, AW; Ghia, P; Pospisilova, S; Stamatopoulos, K; Rosenquist, R, 2015: Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. HAEMATOLOGICA 100(3), p. 370 - 376, doi: 10.3324/haematol.2014.109777
• te Raa, GD; Derks, IAM; Navrkalova, V; Skowronska, A; Moerland, PD; van Laar, J; Oldreive, C; Monsuur, H; Trbusek, M; Malcikova, J; Loden, M; Geisler, CH; Hullein, J; Jethwa, A; Zenz, T; Pospisilova, S; Stankovic, T; van Oers, MHJ; Kater, AP; Eldering, E, 2015: The impact of SF3B1 mutations in CLL on the DNA-damage response. LEUKEMIA 29(5), p. 1133 - 1142, doi: 10.1038/leu.2014.318
• Malcikova, J; Stano-Kozubik, K; Tichy, B; Kantorova, B; Pavlova, S; Tom, N; Radova, L; Smardova, J; Pardy, F; Doubek, M; Brychtova, Y; Mraz, M; Plevova, K; Diviskova, E; Oltova, A; Mayer, J; Pospisilova, S; Trbusek, M, 2015: Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. LEUKEMIA 29(4), p. 877 - 885, doi: 10.1038/leu.2014.297
• Kotaskova, J; Malcikova, J; Diviskova, E; Pavlova, S; Mejstrikova, S; Vranova, V; Plevova, K; Plesingerova, H; Doubek, M; Mayer, J; Pospisilova, S, 2015: 13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS. HAEMATOLOGICA 100, p. 417 - 418
• Kantorova, B; Malcikova, J; Brazdilova, K; Borsky, M; Plevova, K; Smardova, J; Trbusek, M; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2015: Single Cell Analysis Proves the Coexistence of NOTCH1 and TP53 Mutations within the Same Cancer Cells in Patients with Chronic Lymphocytic Leukemia. BLOOD 126(23)
• Tom, N; Malcikova, J; Radova, L; Kantorova, B; Pardy, F; Pavlova, S; Pal, K; Mraz, M; Tichy, B; Doubek, M; Brychtova, Y; Plevova, K; Mayer, J; Trbusek, M; Pospisilova, S, 2015: MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA 100, p. 224 - 225